tirzepatide
‘A War Brewing’ Over GLP-1 Agonist Production
Are glucagon-like peptide-1 agonist drugs such as semaglutide and tirzepatide too complex for 503A and 503B ...
NOVEMBER 21, 2024
How a GLP-1 ‘Shadow System’ Puts Patients’ Safety at Risk
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonist drugs are evading FDA scrutiny and ...
NOVEMBER 7, 2024
'Tail Period' for Compounders Could Ease Weight-Loss Rx Shortages
Compounder should be allowed to produce products beyond the FDA’s current hard compounding cut-off. The ...
OCTOBER 10, 2024
GLP-1RA Use Increases Gastric Food Retention Post-Endoscopy—But Fasting Mitigates This
Although patients appear more likely to retain stomach contents during endoscopic procedures, this risk may ...
MAY 29, 2024
Dangerous Market for Weight-Loss Drugs Grows Online
High demand and short supply of GLP-1 antagonists used to treat diabetes and obesity have led many people desperate ...
DECEMBER 19, 2023
FDA Approves Dual-Targeted Treatment for Type 2 Diabetes
The FDA approved tirzepatide (Mounjaro, Eli Lilly) as an adjunct therapy to diet and exercise for improving ...
MAY 13, 2022
